(CNN) – The crackdown on off-brand weight loss and diabetes treatment drugs is about to take effect, meaning supplies for the treatments are likely to tighten.

A federal deadline to halt sales of the GLP-1 medications arrives this week.

The off-brand products made by compounding pharmacies contain the same active ingredients of Ozempic, Wegovy and others, but they didn’t have the stamp of approval from the Food and Drug Administration.

Many consumers started buying the off-brand, and less expensive, drugs when increased demand of the FDA-sanctioned items led to major shortages.

A few months ago, FDA officials declared the shortages were replenished, so the flexibilities given to the manufacturers of the compounded drugs are about to end.

The Outsourcing Facilities Association filed two lawsuits against the FDA about the removal of Tirzepatide and Semaglutide from the drug shortage list, but judges allowed the FDA’s plan to ban the compounded products to remain in place.

Copyright 2025 CNN Newsource. All rights reserved.